Zentek Provides Update on ZenGUARD(TM) Enhanced Air Filters for the Canadian Market
Zentek (NASDAQ:ZTEK)(TSXV:ZEN) announced updates on the launch of ZenGUARD™ Enhanced Air Filters in the Canadian market. The company is finalizing documentation for manufacturing and sales under its medical device establishment licence (MDEL), targeting initial sales by end of March 2025.
The company has completed its Innovative Solutions Canada Testing Stream contract, making the product eligible for Government of Canada purchases through the Pathway to Commercialization opportunity. Zentek will showcase the filters at BUILDEX Vancouver on February 26-27, 2025.
The India team is working to promote ZenGUARD™ technology adoption by engaging with HVAC manufacturers and industry leaders. Zentek plans to use its Canadian Class I medical device classification as a foundation for U.S. market entry, with an Environmental Protection Agency application currently under review.
Zentek (NASDAQ:ZTEK)(TSXV:ZEN) ha annunciato aggiornamenti sul lancio dei Filtri dell'Aria ZenGUARD™ Enhanced nel mercato canadese. L'azienda sta finalizzando la documentazione per la produzione e le vendite sotto la sua licenza per l'istituzione di dispositivi medici (MDEL), puntando a vendite iniziali entro la fine di marzo 2025.
L'azienda ha completato il contratto del Testing Stream di Innovative Solutions Canada, rendendo il prodotto idoneo per gli acquisti del Governo del Canada attraverso l'opportunità di Pathway to Commercialization. Zentek presenterà i filtri a BUILDEX Vancouver il 26-27 febbraio 2025.
Il team indiano sta lavorando per promuovere l'adozione della tecnologia ZenGUARD™ coinvolgendo i produttori di HVAC e i leader del settore. Zentek prevede di utilizzare la sua classificazione di dispositivo medico di Classe I canadese come base per l'ingresso nel mercato statunitense, con una domanda attualmente in fase di revisione presso l'Agenzia per la Protezione Ambientale.
Zentek (NASDAQ:ZTEK)(TSXV:ZEN) anunció actualizaciones sobre el lanzamiento de los Filtros de Aire ZenGUARD™ Enhanced en el mercado canadiense. La empresa está finalizando la documentación para la fabricación y ventas bajo su licencia de establecimiento de dispositivos médicos (MDEL), con el objetivo de realizar ventas iniciales a finales de marzo de 2025.
La empresa ha completado su contrato con el Testing Stream de Innovative Solutions Canada, lo que hace que el producto sea elegible para compras del Gobierno de Canadá a través de la oportunidad de Pathway to Commercialization. Zentek exhibirá los filtros en BUILDEX Vancouver el 26-27 de febrero de 2025.
El equipo de India está trabajando para promover la adopción de la tecnología ZenGUARD™ al involucrar a fabricantes de HVAC y líderes de la industria. Zentek planea utilizar su clasificación de dispositivo médico Clase I canadiense como base para la entrada en el mercado estadounidense, con una solicitud de la Agencia de Protección Ambiental actualmente en revisión.
Zentek (NASDAQ:ZTEK)(TSXV:ZEN)는 캐나다 시장에서 ZenGUARD™ Enhanced 공기 필터 출시 관련 업데이트를 발표했습니다. 이 회사는 의료 기기 설립 라이센스(MDEL) 하에 제조 및 판매 문서를 최종화하고 있으며, 2025년 3월 말까지 초기 판매를 목표로 하고 있습니다.
회사는 Innovative Solutions Canada Testing Stream 계약을 완료하여 제품이 상업화 경로(Pathway to Commercialization)를 통해 캐나다 정부 구매에 적격하게 되었습니다. Zentek은 2025년 2월 26-27일에 열린 BUILDEX Vancouver에서 필터를 전시할 예정입니다.
인도 팀은 HVAC 제조업체 및 업계 리더들과 협력하여 ZenGUARD™ 기술 채택을 촉진하기 위해 노력하고 있습니다. Zentek은 캐나다의 클래스 I 의료 기기 분류를 바탕으로 미국 시장 진입을 계획하고 있으며, 현재 환경 보호국(EPA) 신청서가 검토 중입니다.
Zentek (NASDAQ:ZTEK)(TSXV:ZEN) a annoncé des mises à jour sur le lancement des Filtres à Air ZenGUARD™ Enhanced sur le marché canadien. L'entreprise finalise la documentation pour la fabrication et la vente sous sa licence d'établissement de dispositifs médicaux (MDEL), visant des ventes initiales d'ici la fin de mars 2025.
L'entreprise a complété son contrat avec le Testing Stream d'Innovative Solutions Canada, rendant le produit éligible aux achats du gouvernement canadien via l'opportunité de Pathway to Commercialization. Zentek présentera les filtres lors de BUILDEX Vancouver les 26-27 février 2025.
L'équipe indienne travaille à promouvoir l'adoption de la technologie ZenGUARD™ en s'engageant avec des fabricants de CVC et des leaders de l'industrie. Zentek prévoit d'utiliser sa classification de dispositif médical de Classe I canadienne comme base pour son entrée sur le marché américain, avec une demande auprès de l'Environmental Protection Agency actuellement en cours d'examen.
Zentek (NASDAQ:ZTEK)(TSXV:ZEN) hat Updates zum Launch der ZenGUARD™ Enhanced Luftfilter auf dem kanadischen Markt bekannt gegeben. Das Unternehmen finalisiert die Dokumentation für die Herstellung und den Verkauf unter seiner medizinischen Geräte-Lizenz (MDEL) und zielt auf erste Verkäufe bis Ende März 2025 ab.
Das Unternehmen hat seinen Vertrag mit dem Testing Stream von Innovative Solutions Canada abgeschlossen, wodurch das Produkt für den Erwerb durch die kanadische Regierung im Rahmen der Pathway to Commercialization-Möglichkeit berechtigt ist. Zentek wird die Filter auf der BUILDEX Vancouver am 26.-27. Februar 2025 präsentieren.
Das indische Team arbeitet daran, die Annahme der ZenGUARD™-Technologie zu fördern, indem es mit HVAC-Herstellern und Branchenführern in Kontakt tritt. Zentek plant, seine kanadische Klassifizierung als medizinisches Gerät der Klasse I als Grundlage für den Markteinstieg in den USA zu nutzen; derzeit wird ein Antrag bei der Umweltschutzbehörde bearbeitet.
- Product eligible for Government of Canada purchases through Pathway to Commercialization
- Initial sales targeted for March 2025
- Expansion plans into U.S. market with EPA application under review
- Established manufacturing partnership with extensive sales network
- Product not yet approved for sale in Canadian market
- Still pending EPA approval for U.S. market entry
Insights
The planned commercialization of ZenGUARD™ Enhanced Air Filters represents a calculated market entry strategy in Canada's $450M+ air filtration market. The MDEL pathway leveraging existing surgical mask approvals significantly reduces regulatory hurdles and time-to-market versus pursuing a new standalone approval. The strategic focus on government procurement through the Innovative Solutions Canada Testing Stream validation creates a potentially stable revenue channel.
The Class I medical device classification is particularly noteworthy as it positions the product in a sweet spot - high enough to command premium pricing and credibility, yet with manageable regulatory requirements. The EPA application review for U.S. market entry indicates a parallel regulatory strategy that could unlock a market roughly 10x larger than Canada.
The timing aligns with heightened focus on indoor air quality following COVID-19, while the sustainability angle addresses growing ESG mandates. However, successful commercialization will hinge on demonstrating clear cost-benefit advantages over existing HEPA and activated carbon solutions that dominate the market.
The strategic expansion into India's rapidly growing air filtration market, projected to reach $2.2B by 2025, represents a significant opportunity. The focus on building local relationships with HVAC manufacturers and distributors is important as India's unique market dynamics often favor companies with strong on-ground presence and cultural understanding.
The target launch timeline of March 2025 for Canadian early adopters appears realistic given the existing regulatory framework. The multi-channel distribution strategy combining direct sales, manufacturing partner networks and government procurement creates diverse revenue streams. The focus on commercial and institutional sectors (healthcare, education) is shrewd as these segments typically have higher willingness to pay for premium filtration solutions.
The emphasis on cost savings and emission reductions in government procurement messaging indicates awareness of key buying criteria. However, success will require clear differentiation and compelling ROI metrics versus established competitors in a market where price sensitivity remains high.
GUELPH, ON / ACCESS Newswire / January 17, 2025 / Zentek Ltd. ("Zentek" or the "Company") (NASDAQ:ZTEK)(TSXV:ZEN), an intellectual property development and commercialization company, is pleased to provide an update on the launch of ZenGUARD™ Enhanced Air Filters in the Canadian Market.
The Company is prioritizing the completion of all required documentation to support the manufacture and sale of ZenGUARD™ Enhanced Air Filters under its existing medical device establishment licence ("MDEL") alongside ZenGUARD™ Surgical Masks. This documentation will be completed in compliance with Canadian Medical Device Regulations (MDR) and ISO 13485:2016 Quality Management System for medical devices.
The Company is targeting initial sales to early adopters by the end of March, 2025.
Zentek's Canadian manufacturing partner will produce finished ZenGUARD™ Enhanced Air Filters, which the Company will then sell directly to its customers and potentially others in the manufacturing partner's extensive sales network.
Zentek has previously completed its Innovative Solutions Canada Testing Stream contract to validate ZenGUARD™ Enhanced Air Filters as a safe and effective device to mitigate the transmission of disease. As a result, this innovation is eligible for purchase by the Government of Canada through the Pathway to Commercialization (PTC) opportunity. Once ZenGUARD™ Enhanced Air Filters are added to the Company's MDEL, Zentek will work diligently with Public Services and Procurement Canada to begin supplying its innovation to the Federal Government and report the associated cost savings and emission reductions to each specific agency.
In addition to its existing distribution agreements, the Company's manufacturing partner's sales channels and the PTC procurement opportunity, the Company will continue attending and exhibiting at industry events to create awareness of its unique value proposition to support sales growth. The next event where the Company will showcase ZenGUARD™ Enhanced Air Filters will be BUILDEX Vancouver on February 26 and 27, 2025.
Zentek's India team is playing a pivotal role in driving the potential adoption of ZenGUARD™ technology by working tirelessly on the ground to build awareness and foster relationships with key stakeholders. With a deep understanding of the local market and its unique challenges, the team is actively engaging with HVAC manufacturers, distributors, and industry leaders to highlight the benefits of ZenGUARD™ in improving indoor air quality.
Zentek will leverage its Class I medical device classification for ZenGUARD™ Enhanced Air Filters in Canada as a strategic foundation for entering the U.S. market. By aligning with rigorous regulatory standards and demonstrating proven efficacy through third-party testing, Zentek can build credibility with U.S. stakeholders, including regulatory bodies, healthcare providers, and HVAC industry leaders. The Company currently has an application under review by the Environmental Protection Agency to sell ZenGUARD Enhanced Air Filters in the US market.
As the demand for effective and energy-efficient air filtration solutions grows across industries, ZenGUARD™ delivers a unique offering that is both effective and sustainable. With Canadian workplaces, healthcare facilities, and educational institutions increasingly prioritizing indoor air quality and decarbonization, the Company believes its launch is well-timed to address these critical needs.
"We're thrilled to bring ZenGUARD™ Enhanced Air Filters to the Canadian market," said Greg Fenton, Zentek CEO. "This innovative technology is not only redefining how we think about air filtration but also delivering tangible benefits for businesses, organizations, and communities. With ZenGUARD™, we are making healthier, safer indoor environments accessible to all."
About Zentek Ltd.
Zentek is an ISO 13485:2016 certified intellectual property technology company focused on the research, development and commercialization of novel products seeking to give the Company's commercial partners a competitive advantage by making their products better, safer, and greener.
Zentek's patented technology platform ZenGUARD™ is shown to have enhanced viral filtration efficiency for surgical masks and aims to do the same for HVAC (heating, ventilation, and air conditioning) systems. Zentek's ZenGUARD™ production facility is in Guelph, Ontario.
For further information on Zentek:
investorrelations@zentek.com
Ryan Shacklock
Senior VP, Strategy & Business Development
Email: rshacklock@zentek.com
Phone: 306-270-9610
To find out more about Zentek, please visit our website at www.Zentek.com. A copy of this news release and all material documents in respect of the Company may be obtained on Zentek's SEDAR+ profile at http://www.sedarplus.ca/.
Forward-Looking Statements
This news release contains forward-looking statements. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Although Zentek believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Zentek disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE: Zentek
View the original press release on ACCESS Newswire
FAQ
When will Zentek (ZTEK) begin selling ZenGUARD Enhanced Air Filters in Canada?
What regulatory approvals does Zentek (ZTEK) need for ZenGUARD air filters in Canada?
Is Zentek (ZTEK) planning to enter the U.S. market with ZenGUARD air filters?
Where will Zentek (ZTEK) showcase ZenGUARD Enhanced Air Filters in early 2025?